Document Detail


HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
MedLine Citation:
PMID:  21891797     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
X-adrenoleukodystrophy (X-ALD) is a peroxisomal metabolic disorder caused by mutations in the ABCD1 gene encoding the peroxisomal ABC transporter adrenoleukodystrophy protein (ALDP). The consistent metabolic abnormality in all forms of X-ALD is an inherited defect in the peroxisomal β-oxidation of very long chain FAs (VLCFAs >C22:0) and the resultant pathognomic accumulation of VLCFA. The accumulation of VLCFA leads to a neuroinflammatory disease process associated with demyelination of the cerebral white matter. The present study underlines the importance of a potent histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA) in inducing the expression of ABCD2 [adrenoleukodystrophy-related protein (ALDRP)], and normalizing the peroxisomal β-oxidation, as well as the saturated and monounsaturated VLCFAs in cultured human skin fibroblasts of X-ALD patients. The expression of ELOVL1, the single elongase catalyzing the synthesis of both saturated VLCFA (C26:0) and monounsaturated VLCFA (C26:1), was also reduced by SAHA treatment. In addition, using Abcd1/Abcd2-silenced mouse primary astrocytes, we also examined the effects of SAHA in VLCFA-induced inflammatory response. SAHA treatment decreased the inflammatory response as expression of inducible nitric oxide synthase, inflammatory cytokine, and activation of NF-κB in Abcd1/Abcd2-silenced mouse primary astrocytes was reduced. These observations indicate that SAHA corrects both the metabolic disease of VLCFA as well as secondary inflammatory disease; therefore, it may be an ideal drug candidate to be tested for X-ALD therapy in humans.
Authors:
Jaspreet Singh; Mushfiquddin Khan; Inderjit Singh
Related Documents :
17160877 - Western diamondback rattlesnakes demonstrate physiological and biochemical strategies f...
8597837 - Rhizomelic chondrodysplasia punctata: report of a case with review of the literature an...
14761087 - The use of low-protein, low-phosphorus, amino acid- and phytase-supplemented diets on l...
17513427 - Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derive...
1421097 - Increased monoamine turnover in the subfornical organ area following body fluid depletion.
11695857 - Anion selective exhaustive injection-sweep-micellar electrokinetic chromatography.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-09-04
Journal Detail:
Title:  Journal of lipid research     Volume:  52     ISSN:  0022-2275     ISO Abbreviation:  J. Lipid Res.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-17     Completed Date:  2012-02-02     Revised Date:  2014-09-20    
Medline Journal Info:
Nlm Unique ID:  0376606     Medline TA:  J Lipid Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2056-69     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ATP-Binding Cassette Transporters / genetics,  metabolism
Acetylation / drug effects
Acetyltransferases / genetics
Adrenoleukodystrophy / genetics,  metabolism,  pathology*
Animals
Astrocytes / drug effects*,  metabolism
Blood-Brain Barrier / drug effects,  metabolism
Cytokines / genetics*
Down-Regulation / drug effects
Fatty Acids / chemistry,  metabolism*
Fibroblasts / cytology,  drug effects*,  metabolism,  pathology
Gene Silencing*
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylases / metabolism
Humans
Hydroxamic Acids / pharmacology*
Inflammation / metabolism
Mice
Nitric Oxide Synthase Type II / genetics
Oxidation-Reduction / drug effects
Oxidative Stress / drug effects
Peroxisomes / drug effects,  metabolism
RNA, Messenger / genetics,  metabolism
Skin / pathology
Grant Support
ID/Acronym/Agency:
C06 RR-015455/RR/NCRR NIH HHS; C06 RR-018823/RR/NCRR NIH HHS; NS-22576/NS/NINDS NIH HHS; NS-37766/NS/NINDS NIH HHS; R01 NS022576/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/ABCD2 protein, mouse; 0/ABCD3 protein, human; 0/Abcd1 protein, mouse; 0/Cytokines; 0/Fatty Acids; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 0/RNA, Messenger; 149647-78-9/vorinostat; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 2.3.1.-/Acetyltransferases; EC 2.3.1.-/fatty acid elongases; EC 3.5.1.98/Histone Deacetylases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In-Region Versus Out-of-Region Hospitalizations at the End of Life Among Older Rural Residents: The ...
Next Document:  Lung lobectomy in a patient with an implantable left ventricular assist device.